212 related articles for article (PubMed ID: 37253131)
21. Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai.
Shi D; Chen J; Zhao M; Tang Y; Zhao C; Jin Y; Tian D; Liao Y; Wang X; Wang W; Fan X; Yi Z; Chen X; Ling Y
J Clin Immunol; 2024 Mar; 44(3):80. PubMed ID: 38462559
[TBL] [Abstract][Full Text] [Related]
22. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
[TBL] [Abstract][Full Text] [Related]
23. COVID-19: lambda interferon against viral load and hyperinflammation.
Andreakos E; Tsiodras S
EMBO Mol Med; 2020 Jun; 12(6):e12465. PubMed ID: 32333818
[TBL] [Abstract][Full Text] [Related]
24. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs.
Bastard P; Vazquez SE; Liu J; Laurie MT; Wang CY; Gervais A; Le Voyer T; Bizien L; Zamecnik C; Philippot Q; Rosain J; Catherinot E; Willmore A; Mitchell AM; Bair R; Garçon P; Kenney H; Fekkar A; Salagianni M; Poulakou G; Siouti E; Sahanic S; Tancevski I; Weiss G; Nagl L; Manry J; Duvlis S; Arroyo-Sánchez D; Paz Artal E; Rubio L; Perani C; Bezzi M; Sottini A; Quaresima V; Roussel L; Vinh DC; Reyes LF; Garzaro M; Hatipoglu N; Boutboul D; Tandjaoui-Lambiotte Y; Borghesi A; Aliberti A; Cassaniti I; Venet F; Monneret G; Halwani R; Sharif-Askari NS; Danielson J; Burrel S; Morbieu C; Stepanovskyy Y; Bondarenko A; Volokha A; Boyarchuk O; Gagro A; Neuville M; Neven B; Keles S; Hernu R; Bal A; Novelli A; Novelli G; Saker K; Ailioaie O; Antolí A; Jeziorski E; Rocamora-Blanch G; Teixeira C; Delaunay C; Lhuillier M; Le Turnier P; Zhang Y; Mahevas M; Pan-Hammarström Q; Abolhassani H; Bompoil T; Dorgham K; ; ; ; Gorochov G; Laouenan C; Rodríguez-Gallego C; Ng LFP; Renia L; Pujol A; Belot A; Raffi F; Allende LM; Martinez-Picado J; Ozcelik T; Imberti L; Notarangelo LD; Troya J; Solanich X; Zhang SY; Puel A; Wilson MR; Trouillet-Assant S; Abel L; Jouanguy E; Ye CJ; Cobat A; Thompson LM; Andreakos E; Zhang Q; Anderson MS; Casanova JL; DeRisi JL
Sci Immunol; 2023 Dec; 8(90):eabp8966. PubMed ID: 35857576
[TBL] [Abstract][Full Text] [Related]
25. Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia.
Su HC; Jing H; Zhang Y; Casanova JL
Annu Rev Immunol; 2023 Apr; 41():561-585. PubMed ID: 37126418
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19.
Eto S; Nukui Y; Tsumura M; Nakagama Y; Kashimada K; Mizoguchi Y; Utsumi T; Taniguchi M; Sakura F; Noma K; Yoshida Y; Ohshimo S; Nagashima S; Okamoto K; Endo A; Imai K; Kanegane H; Ohnishi H; Hirata S; Sugiyama E; Shime N; Ito M; Ohge H; Kido Y; Bastard P; Casanova JL; Tanaka J; Morio T; Okada S
Res Sq; 2022 Mar; ():. PubMed ID: 35291303
[No Abstract] [Full Text] [Related]
27. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Park A; Iwasaki A
Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
[TBL] [Abstract][Full Text] [Related]
28. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
[TBL] [Abstract][Full Text] [Related]
29. Examination of autoantibodies to type I interferon in patients suffering from long COVID.
Hansen KS; Jørgensen SE; Skouboe MK; Agergaard J; Schiøttz-Christensen B; Vibholm LK; Tolstrup M; Østergaard L; Leth S; Mogensen TH
J Med Virol; 2023 Sep; 95(9):e29089. PubMed ID: 37698062
[TBL] [Abstract][Full Text] [Related]
30. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia.
Bastard P; Zhang Q; Cobat A; Jouanguy E; Zhang SY; Abel L; Casanova JL
C R Biol; 2021 Jun; 344(1):19-25. PubMed ID: 34213846
[TBL] [Abstract][Full Text] [Related]
31. Type I and III interferon responses in SARS-CoV-2 infection.
Kim YM; Shin EC
Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323
[TBL] [Abstract][Full Text] [Related]
32. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
Bastard P; Orlova E; Sozaeva L; Lévy R; James A; Schmitt MM; Ochoa S; Kareva M; Rodina Y; Gervais A; Le Voyer T; Rosain J; Philippot Q; Neehus AL; Shaw E; Migaud M; Bizien L; Ekwall O; Berg S; Beccuti G; Ghizzoni L; Thiriez G; Pavot A; Goujard C; Frémond ML; Carter E; Rothenbuhler A; Linglart A; Mignot B; Comte A; Cheikh N; Hermine O; Breivik L; Husebye ES; Humbert S; Rohrlich P; Coaquette A; Vuoto F; Faure K; Mahlaoui N; Kotnik P; Battelino T; Trebušak Podkrajšek K; Kisand K; Ferré EMN; DiMaggio T; Rosen LB; Burbelo PD; McIntyre M; Kann NY; Shcherbina A; Pavlova M; Kolodkina A; Holland SM; Zhang SY; Crow YJ; Notarangelo LD; Su HC; Abel L; Anderson MS; Jouanguy E; Neven B; Puel A; Casanova JL; Lionakis MS
J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33890986
[TBL] [Abstract][Full Text] [Related]
33. Restoration of dendritic cell homeostasis and Type I/Type III interferon levels in convalescent COVID-19 individuals.
Rajamanickam A; Kumar NP; Pandiaraj AN; Selvaraj N; Munisankar S; Renji RM; Venkatramani V; Murhekar M; Thangaraj JWV; Kumar MS; Kumar CPG; Bhatnagar T; Ponnaiah M; Sabarinathan R; Saravanakumar V; Babu S
BMC Immunol; 2022 Oct; 23(1):51. PubMed ID: 36289478
[TBL] [Abstract][Full Text] [Related]
34. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.
Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman.
Ning W; Xu W; Cong X; Fan H; Gilkeson G; Wu X; Hughes H; Jiang W
J Autoimmun; 2022 Oct; 132():102896. PubMed ID: 36029717
[TBL] [Abstract][Full Text] [Related]
36. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation.
Zhang Q; Bastard P; Bolze A; Jouanguy E; Zhang SY; ; Cobat A; Notarangelo LD; Su HC; Abel L; Casanova JL
Med; 2020 Dec; 1(1):14-20. PubMed ID: 33363283
[TBL] [Abstract][Full Text] [Related]
37. Murine Type III interferons are functionally redundant and correlate with bacterial burden during influenza/bacterial super-infection.
Rich HE; Antos D; McCourt CC; Zheng WQ; Devito LJ; McHugh KJ; Gopal R; Wang J; Alcorn JF
PLoS One; 2021; 16(10):e0255309. PubMed ID: 34618816
[TBL] [Abstract][Full Text] [Related]
38. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
Manry J; Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Mégarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs CM; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari FS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Erikstrup C; Condino-Neto A; Prando C; Bondarenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Anderson MS; Boisson B; Béziat V; Zhang SY; Andreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Burdet C; Bouadma L; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Casanova JL; Abel L; Cobat A
Proc Natl Acad Sci U S A; 2022 May; 119(21):e2200413119. PubMed ID: 35576468
[TBL] [Abstract][Full Text] [Related]
39. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling.
Zheng Y; Zhuang MW; Han L; Zhang J; Nan ML; Zhan P; Kang D; Liu X; Gao C; Wang PH
Signal Transduct Target Ther; 2020 Dec; 5(1):299. PubMed ID: 33372174
[TBL] [Abstract][Full Text] [Related]
40. Detection of Neutralizing Anti-Type 1 Interferon Autoantibodies.
Shaw ER; Rosen LB; Ding L; Holland SM; Su HC
Curr Protoc; 2022 Aug; 2(8):e511. PubMed ID: 35976040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
